Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | AXL over exp |
| Therapy | Bemcentinib |
| Indication/Tumor Type | melanoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL over exp | melanoma | sensitive | Bemcentinib | Preclinical - Cell culture | Actionable | In a preclinical study, Bemcentinib (BGB-324) treatment inhibited viability of a BRAF wild-type melanoma cell line overexpressing Axl in culture (PMID: 35332208). | 35332208 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35332208) | AXL inhibition improves BRAF-targeted treatment in melanoma. | Full reference... |